Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06699914 · ClinicalTrials.gov registry record
A Study to Evaluate Real-world Brolucizumab Effectiveness and Safety in Japanese Patients With Neovascular Age-related Macular Degeneration (nAMD)
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 438
- Enrollment target
NCT06699914 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 438 participants.
The verdict
NCT06699914 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 438 participants
- Enrollment target
Study Summary
A retrospective, observational, single-arm, non-randomized cohort study of ocular treatment in nAMD patients in Japan who had records of at least 12 months of follow-up after their first brolucizumab intravitreal injection. Patients who had records of at least 12 months of visits after the first brolucizumab injection (index date) were identified during the index period and were recruited during the data collection/recruitment period.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 438 participants |
| Start Date | 2022-09-06 |
| Est. Completion | 2023-12-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06699914
The ClinicalTrials.gov registry entry for NCT06699914 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 438 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT06699914 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06699914 about?
NCT06699914 is a clinical study titled "A Study to Evaluate Real-world Brolucizumab Effectiveness and Safety in Japanese Patients With Neovascular Age-related Macular Degeneration (nAMD)". A retrospective, observational, single-arm, non-randomized cohort study of ocular treatment in nAMD patients in Japan who had records of at least 12 months of follow-up after their first brolucizumab intravitreal injection. Patients who had records of at least 12 months of visits after the first bro...
What is the current status of trial NCT06699914?
This trial is currently completed. The enrollment target is 438 participants. The study started on 2022-09-06. Estimated completion is 2023-12-01.
Who is sponsoring clinical trial NCT06699914?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.